Publication: 2408

Publication: 2408

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Oncologist vol 22 (2) 189-198

Year:: 2017
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Alliance-data-source,-internal-user
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: Yes
Book Volume:: 6

Parents:: 2040
Children:: None

Program:: OGC
Primary Committee:: Respiratory
Sec. Committees:

Pharmas:
Grants:: CA 033601, NIA 5R21AG042894; CA180821, U10CA180882, VA Career Development Award; CA47559 and NIA 5R21AG042894; CA 47577; CA xxxx; CA xxxx; CA 41287; NIA 5R21AG042894 and PCFB, , U10 CA033601, R21 AG042894, U10 CA180821, U10 CA180836, U10 CA180857, U10 CA180882, P01 CA142538, U10 CA180838, U10 CA180866

Corr. Author:
Authors:: Xiaofei Wang Xiaoyi Wang Lydia Hodgson Stephen L. George Daniel J. Sargent Nate R. Foster Apar Kishor Ganti Thomas E. Stinchcombe Jeffrey Crawford Robert Kratzke Alex A. Adjei Hedy L. Kindler Everett E. Vokes Herbert Pang

Networks:: LAPS-IL057, LAPS-MN026, LAPS-NC010, MN022, NE003

Study: Alliance-A151724
Multiple Studies, or Legacy Studies in Alliance Study:: CALGB-8435, CALGB-8638, CALGB-8833, CALGB-8933, CALGB-9031, CALGB-30101, CALGB-30107, CALGB-30307, CALGB-30601, CALGB-39807, CALGB-9131, CALGB-9234, CALGB-9530, CALGB-9631, CALGB-9733, NCCTG-N0021, NCCTG-N0623
Phases:: N/A, 2

Keywords:: Malignant mesothelioma, Surrogate endpoint, Progression‐free survival, Overall survival, Risk factors